摘要
发达国家约1/3人口患有非酒精性脂肪性肝病（NAFLD）,其中10%-30%的NAFLD表现为非酒精性脂肪性肝炎（NASH）。NAFLD和心血管疾病有共同的代谢危险因素,因此NASH患者肝脏及心血管相关病死率明显增加。主要从改善生活方式、减肥治疗、针对代谢综合征的治疗、胰岛素增敏剂、抗氧化剂类药物治疗及终末期肝病的治疗5个方面介绍了NAFLD的治疗进展。指出了临床医生在NAFLD诊治过程中应更多关注NAFLD伴发的代谢综合征。
Non- alcoholic fatty liver disease（ NAFLD） affects up to a third of the population in developed countries. Between 10% and30% of patients with NAFLD have non- alcoholic steatohepatitis（ NASH）. There are metabolic risk factors common to both NAFLD and cardiovascular disease,so patients with NASH have an increased risk of liver- related and cardiovascular death. This articles reviews the most recent advances in the management of NAFLD in five main areas： lifestyle modification,weight loss treatment,therapy for metabolic syndrome,insulin sensitizer and antioxidant pharmacotherapy,and management of end- stage liver disease. It is pointed out that clinicians need to pay more attention to metabolic syndrome in the diagnosis and treatment of NAFLD.
出处
《临床肝胆病杂志》
CAS
2015年第7期1135-1139,共5页
Journal of Clinical Hepatology
基金
2013-2014年度国家临床重点专科建设项目-感染病科
上海市科委"科技创新行动计划"医学与农业领域重点项目(13401902100)
上海市卫生局临床医学应用研究项目(20114279)
关键词
脂肪肝
治疗
综述
fatty liver
therapy
review
